

BIOTECH ATELIER 2.0

DRAFT AGENDA_v.12

08:00 – 09:00	Registration and Networking Coffee - good chance to talk with a lecturer, organizer or participant in case of early arrival		
09:00 - 09:15	Welcome and Opening of the BioTech Atelier		
	This is the second edition of Biotech Atelier after the great success of the event in 2018. We want to report the progress and look forward for 2020.		
	Dr. Borislav Borissov PhD , Managing Director, Prescriptia		
	Dr. Stanimir Hasurdjiev , Chairman of the Administrative board, Bulgarian Association for Personalized Medicine (BAPEMED) Peter Statev , Chairman of the Supervisory Board, Sofia Tech Park		
09.15 – 10.15	Advanced therapy medicinal products (ATMPs) - ATMPs are the new hope and challenge for diagnosis, therapy, registration, pharmacovigilance. Pricing and reimbursement are big issues as well. The distinguished panelists will elaborate topics related to ATMPs in the EU and Bulgaria and stimulate the guests for a fruitful discussion.		
	in the EU and Bulgaria and stimulate the guests for a fruitful discussion.		
	in the EU and Bulgaria and stimulate the guests for a fruitful discussion. Keynote Lecturer - <u>Prof. Dr. Mondher Thoumi</u> , <u>President and Founder</u> , <u>Creativ-Ceutical</u>		
	in the EU and Bulgaria and stimulate the guests for a fruitful discussion. Keynote Lecturer - <u>Prof. Dr. Mondher Thoumi</u> , <u>President and Founder</u> , <u>Creativ-Ceutical</u> 1. <u>Magda Chlebus</u> , Executive Director, Science Policy and Regulatory Affairs, EFPIA		
	in the EU and Bulgaria and stimulate the guests for a fruitful discussion. Keynote Lecturer - Prof. Dr. Mondher Thoumi, President and Founder, Creativ-Ceutical 1. Magda Chlebus, Executive Director, Science Policy and Regulatory Affairs, EFPIA 2. Dr. Borislav Borissov, Managing Director, Prescriptia		
	in the EU and Bulgaria and stimulate the guests for a fruitful discussion. Keynote Lecturer - <u>Prof. Dr. Mondher Thoumi</u> , <u>President and Founder</u> , <u>Creativ-Ceutical</u> 1. <u>Magda Chlebus</u> , Executive Director, Science Policy and Regulatory Affairs, EFPIA 2. <u>Dr. Borislav Borissov</u> , Managing Director, Prescriptia 3. <u>Prof. Dr. Steffen Thirstrup</u> , Director, NDA Regulatory Advisory Board, NDA Advisory Services Ltd.		
10.15-10.30	in the EU and Bulgaria and stimulate the guests for a fruitful discussion. Keynote Lecturer - Prof. Dr. Mondher Thoumi, President and Founder, Creativ-Ceutical 1. Magda Chlebus, Executive Director, Science Policy and Regulatory Affairs, EFPIA 2. Dr. Borislav Borissov, Managing Director, Prescriptia 3. Prof. Dr. Steffen Thirstrup, Director, NDA Regulatory Advisory Board, NDA Advisory Services Ltd. 4. Peter Kapitein, President and Patient Advocate, Inspire2Live		
10.15-10.30	in the EU and Bulgaria and stimulate the guests for a fruitful discussion. Keynote Lecturer - Prof. Dr. Mondher Thoumi, President and Founder, Creativ-Ceutical 1. Magda Chlebus, Executive Director, Science Policy and Regulatory Affairs, EFPIA 2. Dr. Borislav Borissov, Managing Director, Prescriptia 3. Prof. Dr. Steffen Thirstrup, Director, NDA Regulatory Advisory Board, NDA Advisory Services Ltd. 4. Peter Kapitein, President and Patient Advocate, Inspire2Live 5. Liliya Evtimova-Tichev, QA Validation Engineer, Lonza		

10.30 – 11.30	Al in Healthcare - Artificial Intelligence / Al/ is a hot topic in life sciences and healthcare. Could and would Al replace human intellect in diagnostic process and offer better treatment? Could we rely on Al for better analysis of the drug efficacy and safety? Has the Al already become a better tool for the registration process of drugs? The panel has the answers.				
	Keynote Lecturer – Timm Pauli , Senior Director, Esubmission Services, Head of Regulatory Operations, PharmaLex				
	1. Bruce Magill , Director of Business Development, Personalised Medicine & Connected Health EMEA, SAP				
	2. Dr. Mads Dalsgaard, Senior Vice President, Head of Experimental Medicine & Clinical Development, Lundbeck				
	3. Angela Velkova, Director of Communities and Strategic Relations, EMEA HIMSS Europe GmbH				
	4. Andrew Fried, Business Development Director, Healthcare and Life Sciences Europe, IBM				
11.30-11.45	Presentation: Developments in modern genetic testing – how far and how deep could we go?				
	Paul Jones, Director, Population Genomics, Illumina				
11.45 – 12.45	The MEGA Project - the MEGA project has been started with a lot of enthusiasm and great expectations, but seems to be under prioritized now. Is this true or not? Where is Bulgaria in the MEGA project? The experts have answers and suggestions				
	Keynote Lecturer – <u>Bogi Eliasen, Associated Partner, Copenhagen Institute for Futures Studies</u>				
	1. Paul Jones , Director, Population Genomics, Illumina				
	2. Erik Steinfelder, Director General, BBMRI-ERIC				
	3. Dr. Kate Witkowska, Commercial Partnerships Manager, Genomics England				
	4. Prof. Radka Kaneva , Executive Manager Molecular Medicine Center, Medical University of Sofia				
	5. Dr. Antonio Andreu , Scientific Director, EATRIS				
12.45 – 13.15	INTERVIEW				
	Dr. Dimitar Georgiev, Founder and CEO Paralax Life Sciences				
	with a distinguished guest of the Biotech Atelier				
13.15 – 14.00	Networking Lunch				
14.00 – 15.00	Access to Funding - Funding in	Real World Evidence (RWE) -	Personalized medicine in non-	Regional Partnerships –	
	Life sciences for both start-ups	can RWE change definitely	oncological disciplines – NM	Regional partnerships are of	
	and mature companies is pretty	the pricing model? How IT	Genomix - Personalized medicine	paramount importance for	
	difficult in Bulgaria? Why and	technologies are involved in	was long time related only to	business and science.	
	how can this be improved? RWE However, Bulgaria is far behind				

<u>Keynote – **Jivko Ivanov**,</u> <u>Managing Partner, Simbula</u>

- 1. Paul Gill,
 Managing
 Partner Asia,
 Iota Omega
 Ventures Pte Ltd.
- 2. **Gary Ashford**, Partner, Harbottle and Lewis LLP
- 3. **Milen Ivanov**, CEO Angels Club
- 4. **Peter Kapitein**,
 President and
 Patient Advocate,
 Inspire2Live
- 5. Vladimir
 Danailov, CEO
 InvestSofia
- 6. Valentina
 Milanova,
 Founder and CEO,
 Daye

Keynote – Prof. Dr. Steffen
Thirstrup, Director, NDA
Regulatory Advisory Board,
NDA Advisory Services Ltd.

- Bruce Magill, Director of Business
 Development,
 Personalised Medicine
 & Connected Health
 EMEA, SAP
- Magda Chlebus, Executive Director, Science Policy and Regulatory Affairs, EFPIA
- 3. Andrew Fried,
 Business Development
 Director, Healthcare
 and Life Sciences
 Europe, IBM
- 4. **Jordan Clark**, Chief Commercial Officer, Diaceutics

oncology and chemotherapy. Not anymore, for sure.

Keynote - **Prof. Dr. Ron HN van Schaik**, President European
Society for Pharmacogenomics & Personalised Therapy (ESPT)

- 1. Prof. Dr. Radka Argirova, Virologist, ACC Tokuda Hospital
- 2. **Prof. Dr. Ivaylo Turnev**, Head of Neurology Clinics, UMHAT Aleksandrovska – TBC
- 3. **Prof. Radka Kaneva**, Executive Manager Molecular Medicine Center, Medical University of Sofia
- 4. **Dr. Marc Fackler**, Business Development Manager, Life Codexx
- 5. **Valentin Nikolov**, SGP Biodynamics

other EU countries. We need to change this.

Keynote - Prof. Michael
Rossbach, Head of Technology
Scouting, Eppendorf Group

- Charalampos-Philip Iosifidis, Managing Partner – Europe, Iota Omega Ventures Pte. Ltd.
- 2. **Dr. Alexander Lezhava**, Group leader -Translational Research 1, Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR) Program Director, POLARIS
- 3. **Prof. Osman Ugur Sezerman**, Head of
 Biostatistics and
 medical informatics
 Department, Acıbadem
 Mehmet Ali Aydınlar
 Üniversitesi
- 4. **Sergii Myronenko**, Chairman, Kiev Clinical Research Forum

15.00 – 16.00	EATRIS – BAPEMED	Clinical trials - Bulgaria is one	Biomarkers & Biobanking –	How to keep young
	partnership. Can this	of the best performers in	Biomarkers are of paramount	professionals in Bulgaria –
	cooperation change the	clinical trials in Europe and	importance for personalized	PharmaLex. Brain drain is a big
	landscape?	even worldwide. Why and	medicine. Biobanking might be	problem for Bulgaria. This is a
		how to perform better?	the key for better biomarker	consequence of several
	Dr. Antonio Andreu , Scientific		development. Is this true?	reasons and there will be
	<u>Director, EATRIS</u>	Keynote - Dr. Borislav		panelists pro and con
	<u>Dr. Stanimir Hasurdjiev,</u>	Borissov, Managing Director,	Keynote – Jordan Clark , Chief	remaining in Bulgaria. A real
	<u>Chairman of the Administrative</u>	<u>Prescriptia</u>	Commercial Officer, Diaceutics	HR expert will be the arbiter.
	Board, BAPEMED	1. Dr. Sergii Myronenko,	 Prof. Radka Kaneva, 	
		Chairman, Kiev Clinical	Executive Manager	<u>Keynote – Georgi Kolev, Human</u>
		Research Forum	Molecular Medicine	Capital Director, Simbula
		2. Dr. Kamen Doxev, PSI	Center, Medical	1. Dr. Thomas Dobmeyer,
		Pharma Support	University of Sofia	CEO and Managing
		3. IQVIA representative	2. Dr. Alexander Lezhava,	Partner, PharmaLex
		– TBC	Group leader -	2. Miglena Manova,
			Translational Research 1,	Regulatory Affairs
			Genome Institute of	Manager, PharmaLex
			Singapore (GIS), Agency	3. Prof. Dr. Victoria
				Sarafian , Professor of
			for Science, Technology	Immunology,
			and Research (A*STAR)	Department of Medical
			Program Director,	Biology, Medical
			POLARIS	University of Plovdiv
			3. Dr. Kate Witkowska,	4. Valentina Milanova,
			Commercial Partnerships	Founder and CEO, Daye
			Manager, Genomics	5. Liliya Evtimova-Tichev,
			England	QA Validation Engineer,
			4. Prof. Michael Rossbach,	Lonza
			Head of Technology	6. Anna-Marie
			Scouting, Eppendorf	Vilamovska , Executive
			Group	Director, Working Ideas
			3.335	

			5. Dr. Marc Fackler , Business Development Manager, Life Codexx	
16:00 – 16:30	Networking Coffee			
16.30 – 17.30	How to establish scientific	IT and Life Sciences - a lot of	Is Genomics Bulgaria/ Genomics	Patient advocacy groups in Life
	consortia and apply for EU	experts see the future of both	Southeastern Europe possible?	Sciences – yes, they are
	funding - this is a hot topic in	ecosystem beyond a	Genomic England achieved	important, but their
	front of Horizon Europe. Bulgaria	marriage. Is this the truth or	sensational results. Is this	importance is taken into
	is criticized to be extremely	is too early to dream?	possible in other European	account. What is the state of
	passive, is this true?	-	regions?	art in the EU and in Bulgaria?
		<u>Keynote – Dr. Mads</u>		
	<u>Keynote - TBD</u>	Dalsgaard, Senior Vice	<u>Keynote - Bogi Eliasen,</u>	<u>Keynote - Dr. Stanimir</u>
	1. Prof. Osman Ugur	<u>President, Head of</u>	Associated Partner, Copenhagen	<u>Hasurdjiev</u> , Chairperson of
	Sezermann , Head of	Experimental Medicine &	Institute for Future Studies	Bulgarian National Patients'
	Biostatistics and medical	<u>Clinical Development,</u>		<u>Organization</u>
	informatics Department,	<u>Lundbeck</u>	 Paul Jones, Director, 	1. Piarella Peralta,
	Acıbadem Mehmet Ali	1. Rob Williams, Sr.	Population Genomics,	Patient Advocate,
	Aydınlar Üniversitesi	Director, Regulatory	Illumina	Inspire2Live
	2. Prof. Dr. Victoria	Informatics and Digital	2. Dr. Kate Witkowska,	2. Dr. Petja Stratieva,
	Sarafian , Professor of	Technologies,	Commercial Partnerships	Chairperson of the
	Immunology,	PharmaLex	Manager, Genomics	Board, Retina Bulgaria,
	Department of Medical	2. Andrew Fried,	England	Development Executive
	Biology, Medical	Business Development	3. Prof. Radka Kaneva,	Central & Eastern
	University of Ploydiv	Director, Healthcare	Executive Manager	Europe, Retina
	3. Prof. Michael Rossbach,	and Life Sciences	Molecular Medicine	International
	Head of Technology	Europe, IBM 3. Bruce Maaill. Director	Center, Medical	3. Aneta Piperkova , COO, ProDuCt – PDC,
	Scouting, Eppendorf	3. Bruce Magill, Director of Business	University of Sofia	Member of BAPEMED
	Group	Development,		4. Natalia Maeva,
		Personalised Medicine		4. Natalia Maeva , President, BSPPH - TBC
		Personalisea iviealcine		riesiueiii, barrii - IBC



	& Connected Health EMEA, SAP		
17.30 – 18.30	30 – 18.30 Could Life Sciences make 10% of the GDP in Bulgaria? This is the key question, which we are seeking to answer		
	1. Dr. Dimitar Georgiev , Founder and CEO Paralax Life Sciences		
	2. Evgeni Ivanov , General Manager, Euroconsultants Bulgaria S.A. AD		
	3. Kaloyan Staykov , Institute for Market Economics		
18.30	Closing of Biotech Atelier 2.0		